NTLA logo

NTLAIntellia Therapeutics Inc

$12.11
$0.24
(1.94%)
Today
Closed $12.11
$0.1321
(1.09%)
After Hours
Updated: 07:59 PM EDT
EarningsAug 6
Mkt Cap$1.73B
Vol10.22M
News
all
press releases
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
Zacks
News Placeholder
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Zacks
News Placeholder
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
Zacks
News Placeholder
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +11.60% and -3.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -50.00% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -438.92% and +6.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Key PointsArk Invest added to existing positions in Shopify, Intellia Therapeutics, and GeneDX on Tuesday...
Nasdaq News: Markets
News Placeholder
NTLA Q2 EPS Increased by Brookline Capital Markets
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Stock analysts at Brookline Capital Markets upped their Q2 2026 EPS estimates for Intellia Therapeutics in a report released on Wednesday, April 29th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($0.75...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.